- Location
Eisai
"-
Mylan Today Announced That Subsidiary Mylan Pharmaceuticals and Partner,Banner Pharmacaps
Dec 19, 2013Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. ...
Tags: Mylan, Targretin Suit, Treatment of Cutaneous Manifestations
-
Eisai Has Filed an Application for The Proton Pump Inhibitor Pariet in Japan
Dec 4, 2013Eisai has filed an application for the proton pump inhibitor Pariet in Japan looking for a further indication expansion for use in the prevention of recurrent gastric or duodenal ulcer caused by low-dose aspirin therapy as well as the ...
-
Eisai Europe Has Become a Signatory to The Tuberculosis Drug Accelerator Partnership
Nov 26, 2013Eisai Europe has become a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, an initiative that aims to speed up the discovery of essential new treatments for tuberculosis (TB). Launched in June 2012 through a ...
-
LPI Has Launched Its Generic Rabeprazole Sodium Delayed-release Tablets,20mg
Nov 14, 2013Lupin Pharmaceuticals (LPI), a US subsidiary of India-based Lupin, has launched its generic Rabeprazole Sodium delayed-release tablets, 20mg. Earlier, the company had received final approval from the US Food and Drug Administration (FDA) ...
Tags: Lupin Pharma, tablets
-
Eisai Has Secured Approval From The European Commission on License Extension Application
Oct 8, 2013Japanese pharmaceutical firm Eisai has secured approval from the European Commission (EC) on the license extension application for the use of antiepileptic agent Zonegran (zonisamide) in the treatment of pediatric patients. The EC ...
Tags: Eisai Obtains, Zonegran
-
Eisai Has Rolled out a Higher-dose,Once-daily Aricept 23mg Tablet Formulation
Aug 30, 2013Japanese pharmaceutical firm Eisai Co, through its South Korean marketing subsidiary, has rolled out a higher-dose, once-daily Aricept (donepezil hydrochloride) 23mg tablet formulation used to treat moderate-to-severe Alzheimer's disease ...
Tags: pharmaceutical firm, Medicine
-
Dr Reddy's Laboratories Introduced Donepezil Hydrochloride Tablets 23mg in The US
Jul 30, 2013Dr Reddy's Laboratories, an India-based pharmaceutical company, has introduced Donepezil Hydrochloride tablets 23mg in the US on 26 July 2013. The launch follows the approval of an abbreviated new drug application (ANDA) for the drug by ...
Tags: Drug Aricept, Generic Equivalent
-
Eisai Rolled out Aricept Dry Syrup 1%,a New Medicine for Alzheimer's Disease Treatment
Jun 26, 2013Global pharmaceutical company Eisai has rolled out Aricept Dry Syrup 1%, a new medicine for Alzheimer's disease treatment Aricept (donepezil hydrochloride) in Japan. The formulation received Japan manufacturing and marketing authorization ...
Tags: Eisai, Disease Treatment
-
Eisai to Create an Additional Packaging Facility in The UK
Jun 19, 2013Japanese pharmaceutical company Eisai is all set to invest £8m at its Hatfield, Hertfordshire production plant in the UK to create an additional packaging facility. Eisai Manufacturing, the company's UK manufacturing subsidiary ...
Tags: Pharma Packaging, Eisai
-
Eisai Has Announced The Availability of Belviq (Lorcaserin HCl) CIV Tablets in The US
Jun 13, 2013Eisai has announced the availability of Belviq (lorcaserin HCl) CIV tablets in the US, which is designed for chronic weight management in adults who are overweight with a comorbidity or obesity. Indicated for people with body mass ...
Tags: Eisai, Weight Management Therapy
-
GE Healthcare,Research Collaboration with Eisai on Alzheimer's Disease
May 2, 2013GE Healthcare has entered into research collaboration agreement with Eisai for use of GE Healthcare investigational PET amyloid imaging agent, flutemetamol, to select patients for a phase I clinical trial being conducted by Eisai. The ...
-
Eisai Laboratorios Has Submitted a Marketing Authorization Application for Belviq
Apr 3, 2013Eisai's subsidiary Eisai Laboratorios has submitted a marketing authorization application (MAA) for Belviq (lorcaserin HCl) with the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico. Arena Pharmaceuticals's ...
Tags: Eisai, Mexican Marketing, Belviq
-
The US FDA Has Cleared Eisai's ACIPHEX Sprinkle as 12-Week GERD Therapy
Mar 28, 2013The US FDA has cleared Eisai's ACIPHEX Sprinkle (rabeprazole sodium) as 12-week gastroesophageal reflux disease (GERD) therapy for use in children between one to eleven years age. The approval was based on positive data from multicenter, ...
Tags: FDA, Disease Therapy for Children, Medicine
-
Bosch Annual Sales to Reach Euro 1.5bn Turnover by The End of 2015.
Mar 13, 2013The business yesterday reported a 16% hike in annual sales to euro 914m for 2012, and said that it is planning to reach euro 1.5bn turnover by the end of 2015. The growth figures were helped by a 6% expansion in the overall packaging ...
-
Pharma Packaging Portfolio of Bosch Packaging Will Be Introduced at Technopharm 2013
Feb 7, 2013Bosch Packaging Technology is all set to introduce its pharmaceutical portfolio at TechnoPharm 2013 in Nuremberg, Germany. The portfolio includes Solidlab 1 and 2, the Manesty tablet press Xpress 100, and the high-shear mixer granulator ...
Tags: Bosch Packaging Technology, Packaging, Pharma Packaging Portfolio
